Sequential alterations of microrna expression in hepatocellular carcinoma development and venous metastasis

Chun‐Ming Wong, Carmen Chak‐Lui Wong, Joyce Man‐Fong Lee, Dorothy Ngo‐Yin Fan, Sandy Leung‐Kuen Au, Irene Oi‐Lin Ng – 2 December 2011 – Hepatocellular carcinoma (HCC) is a prevalent cancer with an extremely high mortality rate attributed to HCC metastasis, which is the major cause of tumor recurrence and organ failure. Presence of tumor thrombi in the portal veins (venous metastases) is a clinicopathological feature of metastatic HCCs.

Effects of hypolipidemic agent nordihydroguaiaretic acid on lipid droplets and hepatitis C virus

Gulam H. Syed, Aleem Siddiqui – 2 December 2011 – Hepatitis C virus (HCV) relies on host lipid metabolic pathways for its replication, assembly, secretion, and entry. HCV induces de novo lipogenesis, inhibits β‐oxidation, and lipoprotein export resulting in a lipid‐enriched cellular environment critical for its proliferation. We investigated the effects of a hypolipidemic agent, nordihydroguaiaretic acid (NDGA), on host lipid/fatty acid synthesis and HCV life cycle. NDGA negated the HCV‐induced alteration of host lipid homeostasis.

Human immunodeficiency virus and liver disease forum 2010: Conference proceedings

Kenneth E. Sherman, David L. Thomas, Raymond T. Chung – 2 December 2011 – Liver disease continues to represent a critical mediator of morbidity and mortality in those with human immunodeficiency virus (HIV) infection. The frequent presence and overlap of concomitant injurious processes, including hepatitis C virus and hepatitis B virus infections, hepatoxicity associated with antiretroviral therapeutic agents, alcohol, and other toxins, in the setting of immunosuppression lead to rapid fibrotic progression and early development of end‐stage liver disease.

Magnetic resonance imaging of focal liver lesions: Approach to imaging diagnosis

Kathryn J. Fowler, Jeffrey J. Brown, Vamsi R. Narra – 2 December 2011 – This article is a review of magnetic resonance imaging (MRI) of incidental focal liver lesions. This review provides an overview of liver MRI protocol, diffusion‐weighted imaging, and contrast agents. Additionally, the most commonly encountered benign and malignant lesions are discussed with emphasis on imaging appearance and the diagnostic performance of MRI based on a review of the literature. (HEPATOLOGY 2011)

Multipotent stem/progenitor cells in human biliary tree give rise to hepatocytes, cholangiocytes, and pancreatic islets

Vincenzo Cardinale, Yunfang Wang, Guido Carpino, Cai‐Bin Cui, Manuela Gatto, Massimo Rossi, Pasquale Bartolomeo Berloco, Alfredo Cantafora, Eliane Wauthier, Mark E. Furth, Luca Inverardi, Juan Dominguez‐Bendala, Camillo Ricordi, David Gerber, Eugenio Gaudio, Domenico Alvaro, Lola Reid – 2 December 2011 – Multipotent stem/progenitors are present in peribiliary glands of extrahepatic biliary trees from humans of all ages and in high numbers in hepato‐pancreatic common duct, cystic duct, and hilum.

MicroRNA down‐regulated in human cholangiocarcinoma control cell cycle through multiple targets involved in the G1/S checkpoint

Alexandru V. Olaru, Gabriel Ghiaur, Sumitaka Yamanaka, Delgermaa Luvsanjav, Fangmei An, Irinel Popescu, Sorin Alexandrescu, Sarah Allen, Timothy M. Pawlik, Michael Torbenson, Christos Georgiades, Lewis R. Roberts, Gregory J. Gores, Anne Ferguson‐Smith, Maria I. Almeida, George A. Calin, Esteban Mezey, Florin M. Selaru – 2 December 2011 – MicroRNAs (miRs) recently emerged as prominent regulators of cancer processes.

Multiple ascending dose study of BMS‐790052, a nonstructural protein 5A replication complex inhibitor, in patients infected with hepatitis C virus genotype 1

Richard E. Nettles, Min Gao, Marc Bifano, Ellen Chung, Anna Persson, Thomas C. Marbury, Ronald Goldwater, Michael P. DeMicco, Maribel Rodriguez‐Torres, Apinya Vutikullird, Ernesto Fuentes, Eric Lawitz, Juan Carlos Lopez‐Talavera, Dennis M. Grasela – 2 December 2011 – The antiviral activity, resistance profile, pharmacokinetics (PK), safety, and tolerability of BMS‐790052, a nonstructural protein 5A (NS5A) replication complex inhibitor, were evaluated in a double‐blind, placebo‐controlled, sequential panel, multiple ascending dose study.

Subscribe to